Derivatives of N-[2-(dimethylamine)ethyl]-N-(2-phenylethyl)-aniline as potential polypharmacological ligands of SERT/5-HT6/5-HT7

Jakub Staroń, Dawid Warszycki, Grzegorz Satała, Andrzej J. Bojarski

Department of Medicinal Chemistry, Institute of Pharmacology Polish Academy of Sciences, 12 Smetna Street, 31-343 Cracow, Poland

Depression is a serious mental disorder that cripples the lives of hundreds of millions of people. It is estimated that annual cost associated with depression reaches 800 billion euro (only in Europe).¹

Most commonly used antidepressant drugs (e.g. Fluoxetine, Sertraline) acts as a selective serotonin reuptake inhibitors (SSRI) by inhibiting the serotonin transporter (SERT). Unfortunately, these substances sometime exhibit low efficacy together with many side effects.²

It was revealed, that compounds acting on serotonin receptors (e.g. 5-HT1A, 5-HT6 and 5-HT7) may possess antidepressant properties.³ This led to the development of an augmentation therapy, where SSRI treatment is supplemented by, for example, buspirone which is a partial agonist of 5-HT1A receptor.⁴. Unfortunately, this method brings with it a possibility of dangerous drug interactions and cumulative side effects which can be possibly avoided by a fusion of SERT and agonistic/antagonistic activity in one compound.

Derivatives of N-[2-(dimethylamine)ethyl]-N-(2-phenylethyl)aniline revealed to possess high affinity towards 5-HT6 and 5-HT7 receptors, what more, molecular modeling studies showed their possible high affinity towards SERT. This led to a conclusion that these compounds may act as substances with dual SERT/5-HT6 and/or 5-HT7 activity.

- [1] Gustavsson A. et al. Eur. Neuropsychopharm. 21(10) (2011) 718.
- [2] Kirsch I. et al. PLoS Med. 5(2) (2008) e45.
- [3] Artigas F. Pharmacol. Ther. 137(1) (2013) 119.
- [4] Savitz J. et al. Prog. Neurobiol. 88 (2009) 17.

Acknowledgements

The research was financially supported from the project "Platformex" Pol-Nor/198887/73/2013 from the Polish-Norwegian Research Programme operated by the National Centre for Research and Development under the Norwegian Financial Mechanism 2009–2014.